CML Clinical Trial
Official title:
Prospective Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Achieved Deep Molecular Response With Tyrosine Kinase Inhibitors in Real Life Setting in Argentina - (Argentine Stop Trial)
The principal aim of this study is to evaluate complete molecular remission in patients with chronic myeloid leukemia (CML) in deep molecular response after stopping tyrosine kinase inhibitor (TKI) treatment. The second aim is to characterize the immunological status of patients with CML at the time of TKI interruption and then at 3 months after the interruption.
ARGENTINA STOP TRIAL is a multicentre, open-label, uncontrolled trial to estimate the persistence of molecular remission in patients with chronic phase Chronic Myeloid Leukemia (CML) in Deep Molecular Response after stopping Tyrosine Kinase Inhibitor (TKI) Primary Objective: - To identify the proportion of patients who continue on Major Molecular Response after discontinuing treatment with TKI. Secondary objectives: - To characterize the immunological status of patients with CML at the time of interruption and then at 3 and 12 months after the interruption. Tertiary objective: To evaluate the pharmacoeconomic impact of interrupting the treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Terminated |
NCT01131325 -
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
|
Phase 4 | |
| Active, not recruiting |
NCT03578367 -
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
|
Phase 2 | |
| Completed |
NCT03747679 -
Palatability (Taste) of Oral Formulations of Bosutinib
|
Phase 1 | |
| Completed |
NCT01019317 -
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Not yet recruiting |
NCT06423911 -
A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML
|
Phase 3 | |
| Completed |
NCT03880617 -
Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
|
||
| Completed |
NCT00858572 -
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
|
Phase 1 | |
| Completed |
NCT00684008 -
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
| Not yet recruiting |
NCT06047886 -
CD34 Selection Using the Automated CliniMACS Prodigy
|
Phase 1 | |
| Recruiting |
NCT05823571 -
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
|
Phase 1 | |
| Completed |
NCT00780104 -
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
|
Phase 1 | |
| Recruiting |
NCT06211166 -
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
|
||
| Recruiting |
NCT01762969 -
Treatment Modification Based on Early Assessment of CML Patients
|
Phase 2 | |
| Completed |
NCT00891592 -
Umbilical Cord Blood Transplant for Hematological Malignancies
|
Phase 1 | |
| Terminated |
NCT00776373 -
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00511537 -
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders
|
N/A | |
| Recruiting |
NCT05152537 -
FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia
|